Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest ANX-188 Stories

2013-02-28 16:29:56

Name and ticker symbol changes effective March 11, 2013 SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be "Mast Therapeutics, Inc." Brian M. Culley, Chief Executive Officer, said: "The new corporate identity we announce today is the final step in a transformational process through which we have changed fundamentally this company's priorities, personnel and business...

2013-02-28 16:28:59

- Seeking orphan drug designation in acute limb ischemia (ALI) SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced its plans to develop ANX-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States. Arterial disease resulting...

2013-01-30 08:29:43

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated patient recruitment in its pivotal phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease. Santosh Vetticaden, Chief Medical Officer, said: "The substantial effort that went into the design of this study is reflected by the enthusiasm that we have heard from thought leaders and clinical sites who wish to participate. In particular, the...

2012-12-19 08:25:11

SAN DIEGO, Dec. 19, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that ANX-188 drug product for use in the phase 3 clinical study of ANX-188 (purified poloxamer 188), manufactured using the Company's proprietary purification process, has passed quality control (QC) release specifications at Patheon, the Company's contract manufacturer, and currently is in the quality assurance (QA) release process. The study has been approved by multiple institutional...

2012-10-25 15:24:27

SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today provided details regarding the phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease that it plans to initiate this quarter. The Company will host a conference call today at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time (access information below) to discuss the study. The study will be a randomized, double-blind, two-arm, placebo-controlled study conducted at...

2012-10-23 07:29:53

SAN DIEGO, Oct. 23, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it will hold a conference call at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time on Thursday, October 25, 2012 to review the protocol for its upcoming phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease, which is planned to begin this quarter. (Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a) Interested parties may access the conference...

2012-10-02 02:29:53

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has engaged Theradex® Systems, Inc., a contract research organization with 30 years of experience, to manage the Company's upcoming phase 3 study of ANX-188 (purified poloxamer 188) in sickle cell disease. "The engagement of Theradex is one of the final steps before initiating our phase 3 study of ANX-188 in patients with sickle cell disease experiencing vaso-occlusive...

2012-08-06 02:25:49

SAN DIEGO, Aug. 6, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended June 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a) "We start the second half of 2012 with a strong cash position of over $43 million, reflective of a $3.0 million cash burn for the second quarter," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "With the advice of our Regulatory Advisory Board, we are...

2011-05-09 07:00:00

SAN DIEGO, May 9, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the first quarter ended March 31, 2011. "We are pleased to have completed the acquisition of SynthRx and look forward to meeting with the FDA this year to reach agreement on the protocol for a pivotal phase 3 study of ANX-188 for the treatment of sickle cell crisis," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "In addition, we continue to prepare...